A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Inclusion Criteria

• •Participants must have relapsed or refractory multiple myeloma (RRMM).
• •Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide.
• •Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
• •Participants must have measurable disease during screening.
• •Participants must have adequate organ function.
• •Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.